Clinical Trials Logo

Clinical Trial Summary

To determine the efficacy and safety of bupropion SR for quitting tobacco in smokeless tobacco users.


Clinical Trial Description

CONTEXT: No pharmacotherapies have been shown to increase long-term (≥ 6 month) tobacco abstinence rates among smokeless tobacco (ST) users, although bupropion SR has demonstrated potential efficacy in pilot studies.

OBJECTIVE: To determine the efficacy and safety of bupropion SR for tobacco abstinence among ST users compared with placebo.

DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial conducted between August 2003 to May 2005 at two research centers with a 12-week treatment period and follow-up of smoking status to week 52.

INTERVENTION: Bupropion SR titrated to 150 mg twice daily or placebo for 12 weeks plus weekly behavioral interventions.

Main Outcome Measures: The primary endpoint was 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included the prolonged and continuous tobacco abstinence rates at weeks 12, 24, and 52. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00414180
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 3
Start date August 2003
Completion date May 2005

See also
  Status Clinical Trial Phase
Recruiting NCT03998735 - Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure Phase 1
Completed NCT00265681 - Telephone Counseling for Snuff Users N/A
Completed NCT01369693 - In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus Phase 1
Completed NCT01249339 - In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus Phase 1
Withdrawn NCT01100216 - Human Laboratory Study of Smokeless Tobacco Products N/A
Active, not recruiting NCT02994082 - Treating Smokeless Tobacco Use in Rural Veterans N/A